

Ref. No: 326  
From: Commercial  
Date: 07/02/23  
Subject: biologic medicines in gastroenterology

## REQUEST & RESPONSE

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions:

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

Drug	Number of Patients
Adalimumab - Humira	<5
Adalimumab Biosimilar	113
Filgotinib	<5
Golimumab	<5
Infliximab - Remicade	<5
Infliximab Biosimilar	133
Ozanimod	0
Tofacitinib	18
Upadacitinib	<5
Ustekinumab	83
Vedolizumab	50

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Upadacitinib
- Ustekinumab
- Vedolizumab

We are unable to provide this information.